Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020.
|アブストラクト||Nephrotoxicity occasionally occurs during treatment with immune checkpoint inhibitors (ICIs). Few related studies compare the differences between these drugs. This study aimed to systematically characterize nephrotoxicity after ICI initiation. Data were extracted from the US FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis, including information components (ICs) and reporting odds ratios (RORs), was performed to determine the potential renal toxicity of ICIs. A total of 7,204 reports of renal adverse events (AEs) were identified in the FAERS database. Renal AEs were most commonly reported for nivolumab (46.84%). Strong signals were detected in male patients combined with ICIs. In the clinical application of ICIs, attention should be paid to patients, especially male patients, with acute kidney injury, nephritis, autoimmune nephritis and other nephrotoxic AEs. The use of ICIs is likely to aggravate their condition.|
|投稿者||Qu, Jiaming; Ding, Yanming; Jiang, Kaiwen; Hao, Junxia; Li, Yuanzhi; Zhang, Aijun; Li, Zhaohang; Qi, Guanpeng; Xu, Ze; Liu, Xin; Ma, Juman; Bi, Kaishun; Li, Zuojing|
|ジャーナル名||The Tohoku journal of experimental medicine|
|組織名||School of Pharmacy, Shenyang Pharmaceutical University.;School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical;University.;School of Medical Devices, Shenyang Pharmaceutical University.|